Last reviewed · How we verify
BMS-599626
At a glance
| Generic name | BMS-599626 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-599626 CI brief — competitive landscape report
- BMS-599626 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI